CTVA
CTVA
Corteva, Inc.Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q4-2025 | $3.91B ▲ | $1.27B ▼ | $-552M ▼ | -14.12% ▼ | $-0.82 ▼ | $-178M ▼ |
| Q3-2025 | $2.62B ▼ | $1.28B ▼ | $-320M ▼ | -12.22% ▼ | $-0.47 ▼ | $-24M ▼ |
| Q2-2025 | $6.46B ▲ | $1.69B ▲ | $1.31B ▲ | 20.35% ▲ | $1.93 ▲ | $2.16B ▲ |
| Q1-2025 | $4.42B ▲ | $1.25B ▲ | $652M ▲ | 14.76% ▲ | $0.95 ▲ | $1.12B ▲ |
| Q4-2024 | $3.98B | $1.16B | $-41M | -1.03% | $-0.06 | $450M |
What's going well?
Revenue surged 49% and the company swung to an operating profit, showing strong demand and better efficiency. Gross margins also improved slightly, and cost control looks solid.
What's concerning?
A large 'other' expense wiped out operating gains, leading to a bigger net loss. The bottom line is still negative, and one-off items are distorting results.
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q4-2025 | $4.53B ▲ | $42.84B ▲ | $18.46B ▲ | $24.14B ▼ |
| Q3-2025 | $2.59B ▲ | $42.2B ▲ | $16.74B ▲ | $25.22B ▼ |
| Q2-2025 | $2.14B ▲ | $41.76B ▼ | $15.61B ▼ | $25.91B ▲ |
| Q1-2025 | $2.01B ▼ | $42.12B ▲ | $17.6B ▲ | $24.29B ▲ |
| Q4-2024 | $3.17B | $40.83B | $16.8B | $23.79B |
What's financially strong about this company?
Cash jumped by 75% and debt was cut nearly in half, leaving the company with more cash than debt. Most liabilities are long-term, and the company is collecting from customers faster.
What are the financial risks or weaknesses?
Retained earnings turned negative, meaning recent losses wiped out past profits. Equity fell, and nearly half of assets are intangible, which could be risky if acquisitions disappoint.
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q4-2025 | $-552M ▼ | $4.38B ▲ | $-188M ▼ | $-2.2B ▼ | $1.78B ▲ | $4.15B ▲ |
| Q3-2025 | $-395M ▼ | $193M ▼ | $-157M ▲ | $367M ▲ | $420M ▲ | $36M ▼ |
| Q2-2025 | $1.38B ▲ | $947M ▲ | $-164M ▼ | $-808M ▼ | $22M ▲ | $829M ▲ |
| Q1-2025 | $667M ▲ | $-2.11B ▼ | $-34M ▲ | $995M ▲ | $-1.13B ▼ | $-2.2B ▼ |
| Q4-2024 | $-52M | $4.17B | $-123M | $-3.34B | $666M | $3.99B |
What's strong about this company's cash flow?
The company generated a massive amount of cash this quarter, easily covering all expenses, debt repayments, and shareholder returns. Cash flow quality is high, with real cash coming in, not just accounting profits.
What are the cash flow concerns?
Much of the cash flow jump came from one-time working capital changes, which may not repeat. Net income remains negative, so underlying profitability is still a concern.
Revenue by Products
| Product | Q1-2025 | Q2-2025 | Q3-2025 | Q4-2025 |
|---|---|---|---|---|
Biologicals | $80.00M ▲ | $100.00M ▲ | $150.00M ▲ | $190.00M ▲ |
Crop Protection | $1.71Bn ▲ | $1.92Bn ▲ | $1.70Bn ▼ | $2.17Bn ▲ |
Fungicides | $300.00M ▲ | $340.00M ▲ | $220.00M ▼ | $270.00M ▲ |
Herbicides | $860.00M ▲ | $990.00M ▲ | $810.00M ▼ | $1.06Bn ▲ |
Insecticides | $340.00M ▲ | $440.00M ▲ | $410.00M ▼ | $490.00M ▲ |
Other | $130.00M ▲ | $50.00M ▼ | $110.00M ▲ | $160.00M ▲ |
Seed | $2.71Bn ▲ | $4.54Bn ▲ | $920.00M ▼ | $1.74Bn ▲ |
Revenue by Geography
| Region | Q1-2019 | Q2-2025 | Q3-2025 |
|---|---|---|---|
Crop Protection | $0 ▲ | $520.00M ▲ | $770.00M ▲ |
Seed | $0 ▲ | $280.00M ▲ | $390.00M ▲ |
Asia Pacific | $1.46Bn ▲ | $0 ▼ | $0 ▲ |
E M E A | $2.11Bn ▲ | $0 ▼ | $0 ▲ |
Latin America | $470.00M ▲ | $0 ▼ | $0 ▲ |
UNITED STATES | $2.25Bn ▲ | $0 ▼ | $0 ▲ |
Q4 2025 Earnings Call Summary
Read Call Summary5-Year Trend Analysis
A comprehensive look at Corteva, Inc.'s financial evolution and strategic trajectory over the past five years.
Corteva combines a steadily growing revenue base with improving operating margins, supported by strong recent performance in operating and free cash flow. Its balance sheet is conservative, with solid liquidity and relatively low leverage, giving it flexibility to navigate agricultural cycles. Competitively, it benefits from powerful brands, a global distribution network, and a large portfolio of patented traits and crop protection products, all reinforced by substantial and rising R&D investment. The company’s integrated approach—seeds, crop protection, biologicals, and digital tools—creates a differentiated offering and deep customer relationships.
Key risks include volatile earnings, as net income and earnings per share have not yet regained earlier highs despite better operating performance, and retained earnings have slipped into negative territory, reflecting an uneven history of profitability and capital returns. Rising overhead costs and growing short-term liabilities point to ongoing pressure on margins and working capital. At the industry level, Corteva faces intense competition, patent expirations, regulatory scrutiny of seeds and chemicals, and exposure to commodity prices and weather patterns. The planned separation of its seed and crop protection businesses introduces additional strategic and operational execution risk.
The overall picture is of a financially sound, innovation-driven agriscience company with improving cash-generation and a strong competitive platform, but with earnings volatility and execution challenges that cannot be ignored. If Corteva can sustain recent gains in operating and free cash flow, keep overhead in check, and smoothly manage its business separation while continuing to deliver high-value innovations, its financial profile could gradually strengthen. At the same time, the agricultural sector’s inherent cyclicality and regulatory intensity mean that performance is likely to remain uneven year to year, even if the long-term demand for higher-yield, more sustainable farming practices continues to provide a supportive backdrop.
About Corteva, Inc.
https://www.corteva.comCorteva, Inc. operates in the agriculture business. It operates through two segments, Seed and Crop Protection. The Seed segment develops and supplies advanced germplasm and traits that produce optimum yield for farms. It offers trait technologies that enhance resistance to weather, disease, insects, and herbicides used to control weeds, as well as food and nutritional characteristics.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q4-2025 | $3.91B ▲ | $1.27B ▼ | $-552M ▼ | -14.12% ▼ | $-0.82 ▼ | $-178M ▼ |
| Q3-2025 | $2.62B ▼ | $1.28B ▼ | $-320M ▼ | -12.22% ▼ | $-0.47 ▼ | $-24M ▼ |
| Q2-2025 | $6.46B ▲ | $1.69B ▲ | $1.31B ▲ | 20.35% ▲ | $1.93 ▲ | $2.16B ▲ |
| Q1-2025 | $4.42B ▲ | $1.25B ▲ | $652M ▲ | 14.76% ▲ | $0.95 ▲ | $1.12B ▲ |
| Q4-2024 | $3.98B | $1.16B | $-41M | -1.03% | $-0.06 | $450M |
What's going well?
Revenue surged 49% and the company swung to an operating profit, showing strong demand and better efficiency. Gross margins also improved slightly, and cost control looks solid.
What's concerning?
A large 'other' expense wiped out operating gains, leading to a bigger net loss. The bottom line is still negative, and one-off items are distorting results.
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q4-2025 | $4.53B ▲ | $42.84B ▲ | $18.46B ▲ | $24.14B ▼ |
| Q3-2025 | $2.59B ▲ | $42.2B ▲ | $16.74B ▲ | $25.22B ▼ |
| Q2-2025 | $2.14B ▲ | $41.76B ▼ | $15.61B ▼ | $25.91B ▲ |
| Q1-2025 | $2.01B ▼ | $42.12B ▲ | $17.6B ▲ | $24.29B ▲ |
| Q4-2024 | $3.17B | $40.83B | $16.8B | $23.79B |
What's financially strong about this company?
Cash jumped by 75% and debt was cut nearly in half, leaving the company with more cash than debt. Most liabilities are long-term, and the company is collecting from customers faster.
What are the financial risks or weaknesses?
Retained earnings turned negative, meaning recent losses wiped out past profits. Equity fell, and nearly half of assets are intangible, which could be risky if acquisitions disappoint.
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q4-2025 | $-552M ▼ | $4.38B ▲ | $-188M ▼ | $-2.2B ▼ | $1.78B ▲ | $4.15B ▲ |
| Q3-2025 | $-395M ▼ | $193M ▼ | $-157M ▲ | $367M ▲ | $420M ▲ | $36M ▼ |
| Q2-2025 | $1.38B ▲ | $947M ▲ | $-164M ▼ | $-808M ▼ | $22M ▲ | $829M ▲ |
| Q1-2025 | $667M ▲ | $-2.11B ▼ | $-34M ▲ | $995M ▲ | $-1.13B ▼ | $-2.2B ▼ |
| Q4-2024 | $-52M | $4.17B | $-123M | $-3.34B | $666M | $3.99B |
What's strong about this company's cash flow?
The company generated a massive amount of cash this quarter, easily covering all expenses, debt repayments, and shareholder returns. Cash flow quality is high, with real cash coming in, not just accounting profits.
What are the cash flow concerns?
Much of the cash flow jump came from one-time working capital changes, which may not repeat. Net income remains negative, so underlying profitability is still a concern.
Revenue by Products
| Product | Q1-2025 | Q2-2025 | Q3-2025 | Q4-2025 |
|---|---|---|---|---|
Biologicals | $80.00M ▲ | $100.00M ▲ | $150.00M ▲ | $190.00M ▲ |
Crop Protection | $1.71Bn ▲ | $1.92Bn ▲ | $1.70Bn ▼ | $2.17Bn ▲ |
Fungicides | $300.00M ▲ | $340.00M ▲ | $220.00M ▼ | $270.00M ▲ |
Herbicides | $860.00M ▲ | $990.00M ▲ | $810.00M ▼ | $1.06Bn ▲ |
Insecticides | $340.00M ▲ | $440.00M ▲ | $410.00M ▼ | $490.00M ▲ |
Other | $130.00M ▲ | $50.00M ▼ | $110.00M ▲ | $160.00M ▲ |
Seed | $2.71Bn ▲ | $4.54Bn ▲ | $920.00M ▼ | $1.74Bn ▲ |
Revenue by Geography
| Region | Q1-2019 | Q2-2025 | Q3-2025 |
|---|---|---|---|
Crop Protection | $0 ▲ | $520.00M ▲ | $770.00M ▲ |
Seed | $0 ▲ | $280.00M ▲ | $390.00M ▲ |
Asia Pacific | $1.46Bn ▲ | $0 ▼ | $0 ▲ |
E M E A | $2.11Bn ▲ | $0 ▼ | $0 ▲ |
Latin America | $470.00M ▲ | $0 ▼ | $0 ▲ |
UNITED STATES | $2.25Bn ▲ | $0 ▼ | $0 ▲ |
Q4 2025 Earnings Call Summary
Read Call Summary5-Year Trend Analysis
A comprehensive look at Corteva, Inc.'s financial evolution and strategic trajectory over the past five years.
Corteva combines a steadily growing revenue base with improving operating margins, supported by strong recent performance in operating and free cash flow. Its balance sheet is conservative, with solid liquidity and relatively low leverage, giving it flexibility to navigate agricultural cycles. Competitively, it benefits from powerful brands, a global distribution network, and a large portfolio of patented traits and crop protection products, all reinforced by substantial and rising R&D investment. The company’s integrated approach—seeds, crop protection, biologicals, and digital tools—creates a differentiated offering and deep customer relationships.
Key risks include volatile earnings, as net income and earnings per share have not yet regained earlier highs despite better operating performance, and retained earnings have slipped into negative territory, reflecting an uneven history of profitability and capital returns. Rising overhead costs and growing short-term liabilities point to ongoing pressure on margins and working capital. At the industry level, Corteva faces intense competition, patent expirations, regulatory scrutiny of seeds and chemicals, and exposure to commodity prices and weather patterns. The planned separation of its seed and crop protection businesses introduces additional strategic and operational execution risk.
The overall picture is of a financially sound, innovation-driven agriscience company with improving cash-generation and a strong competitive platform, but with earnings volatility and execution challenges that cannot be ignored. If Corteva can sustain recent gains in operating and free cash flow, keep overhead in check, and smoothly manage its business separation while continuing to deliver high-value innovations, its financial profile could gradually strengthen. At the same time, the agricultural sector’s inherent cyclicality and regulatory intensity mean that performance is likely to remain uneven year to year, even if the long-term demand for higher-yield, more sustainable farming practices continues to provide a supportive backdrop.

CEO
Charles Victor Magro (Chem), MBA
Compensation Summary
(Year 2024)
Upcoming Earnings
ETFs Holding This Stock
Summary
Showing Top 3 of 610
Ratings Snapshot
Rating : B+
Most Recent Analyst Grades
Mizuho
Outperform
RBC Capital
Outperform
Wells Fargo
Overweight
Citigroup
Neutral
JP Morgan
Neutral
Oppenheimer
Outperform
Grade Summary
Showing Top 6 of 13
Price Target
Institutional Ownership
VANGUARD GROUP INC
Shares:80.54M
Value:$6.45B
BLACKROCK, INC.
Shares:59.61M
Value:$4.78B
BLACKROCK INC.
Shares:53.66M
Value:$4.3B
Summary
Showing Top 3 of 1,786

